Physician profile
Robert A Pleyo
NPI 1861631384
$5,785.55
in general payments reported to CMS, 2019-2025
15 companies · $1,126 in 2025
The $1,126 reported for 2025 was more than what 86% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $271 · 2022: $320 · 2023: $3,296 · 2024: $772 · 2025: $1,126.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,643 · Consulting Fee: $1,500 · Travel and Lodging: $1,051.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,643.30 |
| Consulting Fee | $1,500.00 |
| Travel and Lodging | $1,050.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $3,104.01 | 2023-2024 | Korsuva, Velphoro |
| Astrazeneca Pharmaceuticals LP | $654.74 | 2021-2025 | Farxiga, Lokelma |
| Travere Therapeutics, INC. | $422.85 | 2023-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $295.32 | 2024-2025 | Jynarque, Voyxact |
| Bayer Healthcare Pharmaceuticals INC. | $202.01 | 2022-2024 | |
| Akebia Therapeutics INC | $175.54 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $143.62 | 2025 | Jardiance |
| Ardelyx, INC. | $142.81 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Medtronic, INC. | $130.47 | 2025 | Symplicity G3 |
| Vifor Pharma, INC. | $123.93 | 2022 | |
| Amgen INC. | $122.62 | 2025 | Tavneos |
| Novo Nordisk INC | $122.29 | 2025 | Ozempic |
| Alexion Pharmaceuticals, INC. | $92.03 | 2024 | Strensiq |
| Novartis Pharmaceuticals Corporation | $32.89 | 2024-2025 | |
| Aurinia Pharma U.S., INC. | $20.42 | 2024 | Lupkynis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Pleyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.